v3.25.4
REVENUES - Summary of Disaggregation of Revenues (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Disaggregation of Revenue [Line Items]      
Total revenues $ 29,443 $ 28,754 $ 27,116
U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 20,876 20,591 19,438
Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 5,064 4,634 4,310
Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 3,503 3,529 3,368
Product sales      
Disaggregation of Revenue [Line Items]      
Total revenues 28,915 28,610 26,934
Product sales | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 20,816 20,508 19,377
Product sales | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 4,617 4,576 4,197
Product sales | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 3,483 3,526 3,361
Total HIV      
Disaggregation of Revenue [Line Items]      
Total revenues 20,752 19,612 18,175
Total HIV | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 16,904 15,918 14,848
Total HIV | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 2,392 2,339 2,102
Total HIV | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 1,456 1,355 1,226
Biktarvy      
Disaggregation of Revenue [Line Items]      
Total revenues 14,334 13,423 11,850
Biktarvy | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 11,467 10,855 9,692
Biktarvy | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 1,676 1,509 1,253
Biktarvy | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 1,190 1,060 905
Descovy      
Disaggregation of Revenue [Line Items]      
Total revenues 2,758 2,113 1,985
Descovy | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 2,559 1,902 1,771
Descovy | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 93 100 100
Descovy | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 105 110 114
Genvoya      
Disaggregation of Revenue [Line Items]      
Total revenues 1,498 1,762 2,060
Genvoya | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 1,281 1,498 1,752
Genvoya | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 148 180 205
Genvoya | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 69 84 103
Odefsey      
Disaggregation of Revenue [Line Items]      
Total revenues 1,167 1,288 1,350
Odefsey | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 881 957 1,012
Odefsey | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 246 290 294
Odefsey | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 40 41 44
Symtuza - Revenue share      
Disaggregation of Revenue [Line Items]      
Total revenues 495 592 529
Symtuza - Revenue share | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 363 450 382
Symtuza - Revenue share | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 120 130 133
Symtuza - Revenue share | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 12 12 13
Other HIV      
Disaggregation of Revenue [Line Items]      
Total revenues 500 434 401
Other HIV | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 352 257 238
Other HIV | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 109 129 116
Other HIV | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 40 48 47
Total Oncology      
Disaggregation of Revenue [Line Items]      
Total revenues 3,236 3,289 2,932
Total Oncology | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 1,626 1,798 1,833
Total Oncology | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 1,102 1,098 875
Total Oncology | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 508 393 224
Total Cell Therapy      
Disaggregation of Revenue [Line Items]      
Total revenues 1,839 1,973 1,869
Total Cell Therapy | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 748 896 1,055
Total Cell Therapy | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 755 804 658
Total Cell Therapy | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 335 274 156
Tecartus      
Disaggregation of Revenue [Line Items]      
Total revenues 344 403 370
Tecartus | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 153 234 245
Tecartus | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 158 138 110
Tecartus | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 32 31 15
Yescarta      
Disaggregation of Revenue [Line Items]      
Total revenues 1,495 1,570 1,498
Yescarta | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 595 662 811
Yescarta | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 598 666 547
Yescarta | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 303 242 140
Trodelvy      
Disaggregation of Revenue [Line Items]      
Total revenues 1,397 1,315 1,063
Trodelvy | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 877 902 777
Trodelvy | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 347 294 217
Trodelvy | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 173 119 68
Total Liver Disease      
Disaggregation of Revenue [Line Items]      
Total revenues 3,217 3,021 2,784
Total Liver Disease | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 1,619 1,601 1,421
Total Liver Disease | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 671 545 511
Total Liver Disease | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 927 876 852
Sofosbuvir/Velpatasvir      
Disaggregation of Revenue [Line Items]      
Total revenues 1,272 1,596 1,537
Sofosbuvir/Velpatasvir | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 636 922 859
Sofosbuvir/Velpatasvir | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 292 299 323
Sofosbuvir/Velpatasvir | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 344 374 355
Vemlidy      
Disaggregation of Revenue [Line Items]      
Total revenues 1,070 959 862
Vemlidy | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 507 486 410
Vemlidy | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 49 44 38
Vemlidy | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 514 428 414
Other Liver Disease      
Disaggregation of Revenue [Line Items]      
Total revenues 874 467 385
Other Liver Disease | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 476 192 152
Other Liver Disease | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 330 202 150
Other Liver Disease | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 69 73 83
Veklury      
Disaggregation of Revenue [Line Items]      
Total revenues 911 1,799 2,184
Veklury | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 470 892 972
Veklury | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 151 284 408
Veklury | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 290 623 805
Total Other      
Disaggregation of Revenue [Line Items]      
Total revenues 799 889 859
Total Other | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 197 299 304
Total Other | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 300 310 301
Total Other | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 302 280 255
AmBisome      
Disaggregation of Revenue [Line Items]      
Total revenues 509 533 492
AmBisome | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 20 44 43
AmBisome | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 267 276 260
AmBisome | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 221 212 189
Other      
Disaggregation of Revenue [Line Items]      
Total revenues 290 356 367
Other | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 177 255 261
Other | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 32 34 40
Other | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues 81 68 66
Royalty, contract and other revenues      
Disaggregation of Revenue [Line Items]      
Total revenues 527 144 182
Royalty, contract and other revenues | U.S.      
Disaggregation of Revenue [Line Items]      
Total revenues 60 82 62
Royalty, contract and other revenues | Europe      
Disaggregation of Revenue [Line Items]      
Total revenues 447 58 114
Royalty, contract and other revenues | Rest of World      
Disaggregation of Revenue [Line Items]      
Total revenues $ 20 $ 4 $ 7